DNA methyltransferase 1

DNA methyltransferase 1 is a maintenance methyltransferase that preserves cytosine methylation patterns after DNA replication. It plays a central role in epigenetic inheritance, genome stability, and transcriptional repression across metazoans. DNMT1 is widely studied in contexts ranging from embryogenesis to cancer, with links to cell cycle control, chromatin modification, and human disease.

Structure and domains

DNMT1 contains multiple conserved domains arranged to coordinate substrate recognition and catalysis, with an N-terminal regulatory region and a C-terminal catalytic domain. Structural studies relate DNMT1 architecture to approaches used by Rosalind Franklin, Max Perutz, John Kendrew, Linus Pauling in macromolecular analysis; crystallographic work by groups associated with Royal Society and European Molecular Biology Laboratory revealed features shared with prokaryotic methyltransferases studied by teams at Cold Spring Harbor Laboratory, Massachusetts Institute of Technology, and Stanford University. The N-terminal region includes a proliferating cell nuclear antigen (PCNA)-binding domain that interfaces with replication machinery such as PCNA, and a replication foci targeting sequence that cooperates with factors described by researchers at Harvard University and University of Cambridge. Other N-terminal motifs include a CXXC-type zinc finger and bromo-adjacent homology elements that resemble domains characterized in work from Max Planck Society and Karolinska Institutet. The catalytic C-terminal domain adopts a methyltransferase fold homologous to enzymes analyzed by investigators at University of Oxford and Yale University; active site residues were mapped in studies comparable to those from Cold Spring Harbor Laboratory and Scripps Research.

Function and catalytic activity

DNMT1 enzymatically transfers a methyl group from S-adenosylmethionine to cytosine in CpG dinucleotides, maintaining methylation signatures first established by de novo methyltransferases characterized in laboratories at Institut Pasteur and University College London. Its substrate specificity for hemimethylated DNA links DNMT1 action to replication forks coordinated by CDC45 and replisome components investigated at institutions like Broad Institute and European Bioinformatics Institute. DNMT1 activity influences chromatin states examined in studies from Cold Spring Harbor Laboratory and Weizmann Institute of Science, and it cooperates with histone-modifying enzymes described by teams at University of California, San Francisco and University of Pennsylvania. Enzymatic kinetics and inhibition profiles have been explored in collaborative projects involving Eli Lilly and Company, Pfizer, and academic groups at University of Tokyo and University of Toronto.

Regulation and interacting partners

DNMT1 is regulated at transcriptional, post-transcriptional, and post-translational levels through interactions with proteins and complexes studied by researchers at National Institutes of Health, European Molecular Biology Laboratory, and Johns Hopkins University. Key interacting partners include chromatin factors such as UHRF1, histone deacetylases characterized by labs at EMBL-EBI and Cold Spring Harbor Laboratory, and replication proteins like PCNA and MCM complex members analyzed at University of Cambridge. Post-translational modifiers such as kinases investigated at Max Planck Institute for Biochemistry and ubiquitin ligases studied at Rockefeller University modulate DNMT1 stability and activity. Regulatory circuits involving noncoding RNAs and transcription factors reported by groups at Massachusetts General Hospital and University of California, San Diego further tune DNMT1 expression during the cell cycle and in response to signaling pathways explored at Dana-Farber Cancer Institute and Salk Institute.

Role in development and disease

DNMT1 is essential for mammalian development as shown in genetic models developed at Harvard Medical School, MIT, and University of California, Berkeley; loss-of-function alleles produce embryonic lethality and developmental defects. Aberrant DNMT1 activity contributes to oncogenesis and tumor progression in studies from MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Mayo Clinic; hypermethylation at tumor suppressor loci and global hypomethylation are recurrent features in cancers cataloged by consortia such as The Cancer Genome Atlas and International Agency for Research on Cancer. Germline mutations in DNMT1 underlie neurological syndromes described in clinical reports from Cleveland Clinic and Great Ormond Street Hospital, and somatic alterations link to age-related diseases investigated by National Institute on Aging and Wellcome Trust. Therapeutic targeting of DNMT1 with nucleoside analogs and small molecules has been pursued in trials organized by European Medicines Agency, US Food and Drug Administration, and pharmaceutical groups including Novartis and Bristol-Myers Squibb.

Genetics and isoforms

The DNMT1 gene maps to human chromosome regions mapped by consortia including Human Genome Project and 1000 Genomes Project, and displays alternative splicing that yields multiple isoforms described in transcriptomic surveys from ENCODE Project and Genotype-Tissue Expression Project. Mouse and zebrafish orthologs characterized at Jackson Laboratory and Zebrafish International Resource Center provide comparative models for functional studies performed at European Molecular Biology Laboratory and Cold Spring Harbor Laboratory. Polymorphisms and mutations cataloged in databases curated by ClinVar and LOVD are used to interpret genotype–phenotype correlations in populations genotyped by UK Biobank and Centers for Disease Control and Prevention. Category:Epigenetics